94 related articles for article (PubMed ID: 32579941)
1. Targeting Bim via a lncRNA Morrbid Regulates the Survival of Preleukemic and Leukemic Cells.
Cai Z; Aguilera F; Ramdas B; Daulatabad SV; Srivastava R; Kotzin JJ; Carroll M; Wertheim G; Williams A; Janga SC; Zhang C; Henao-Mejia J; Kapur R
Cell Rep; 2020 Jun; 31(12):107816. PubMed ID: 32579941
[TBL] [Abstract][Full Text] [Related]
2. Hyperglycemia cooperates with Tet2 heterozygosity to induce leukemia driven by proinflammatory cytokine-induced lncRNA Morrbid.
Cai Z; Lu X; Zhang C; Nelanuthala S; Aguilera F; Hadley A; Ramdas B; Fang F; Nephew K; Kotzin JJ; Williams A; Henao-Mejia J; Haneline L; Kapur R
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33090974
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis.
Cai Z; Kotzin JJ; Ramdas B; Chen S; Nelanuthala S; Palam LR; Pandey R; Mali RS; Liu Y; Kelley MR; Sandusky G; Mohseni M; Williams A; Henao-Mejia J; Kapur R
Cell Stem Cell; 2018 Dec; 23(6):833-849.e5. PubMed ID: 30526882
[TBL] [Abstract][Full Text] [Related]
4. Driver Mutations in Leukemia Promote Disease Pathogenesis through a Combination of Cell-Autonomous and Niche Modulation.
Ramdas B; Mali RS; Palam LR; Pandey R; Cai Z; Pasupuleti SK; Burns SS; Kapur R
Stem Cell Reports; 2020 Jul; 15(1):95-109. PubMed ID: 32502465
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.
Wang X; Zhang L; Zhao F; Xu R; Jiang J; Zhang C; Liu H; Huang H
Ann Hematol; 2018 Aug; 97(8):1375-1389. PubMed ID: 29654398
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
7. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
[TBL] [Abstract][Full Text] [Related]
8. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
9. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
[TBL] [Abstract][Full Text] [Related]
10. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
[TBL] [Abstract][Full Text] [Related]
11. Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia.
Cai Z; Zhang C; Kotzin JJ; Williams A; Henao-Mejia J; Kapur R
Blood Adv; 2020 Jul; 4(14):3246-3251. PubMed ID: 32697817
[TBL] [Abstract][Full Text] [Related]
12. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.
Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056
[TBL] [Abstract][Full Text] [Related]
13. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
14. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
16. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
[TBL] [Abstract][Full Text] [Related]
18. The long non-coding RNA Morrbid regulates Bim and short-lived myeloid cell lifespan.
Kotzin JJ; Spencer SP; McCright SJ; Kumar DBU; Collet MA; Mowel WK; Elliott EN; Uyar A; Makiya MA; Dunagin MC; Harman CCD; Virtue AT; Zhu S; Bailis W; Stein J; Hughes C; Raj A; Wherry EJ; Goff LA; Klion AD; Rinn JL; Williams A; Flavell RA; Henao-Mejia J
Nature; 2016 Sep; 537(7619):239-243. PubMed ID: 27525555
[TBL] [Abstract][Full Text] [Related]
19. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
20. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
Brown P; Meshinchi S; Levis M; Alonzo TA; Gerbing R; Lange B; Arceci R; Small D
Blood; 2004 Sep; 104(6):1841-9. PubMed ID: 15166029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
